Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKLB1028 in advanced solid tumors
NCT05072522Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruserontinib in solid tumor (advanced stage), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose limiting toxicity, Maximum tolerated dose and 1 more. Status: unknown.
02
Drugs
ruserontinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05072522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05072522.